Litcius/Paper detail

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Christian Taucher, Rajeka Lazarus, Hanna Dellago, Gabriele Maurer, Petronela Weisova, Irena Corbic Ramljak, Katrin Dubischar, Anders Lilja, Susanne Eder-Lingelbach, Romana Hochreiter, Juan Carlos Jaramillo, Helga Junker, Michael Krammer, Petra Pusic, Benedicte Querton, Julian Larcher‐Senn, Markus Hoffmann, Stefan Pöhlmann, Adam Finn

2023Journal of Infection16 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicitySeroconversionVaccinationMedicineBooster doseVirologyBooster (rocketry)Adverse effectVirusNeutralizing antibodyImmunologyAntibodyInternal medicineTiterPhysicsAstronomySARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesVaccine Coverage and Hesitancy
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial | Litcius